Whole exome sequencing (WES) is a powerful tool to investigate genetic variations underlying cancers, Mendelian diseases, and complex human disorders. Targeting only protein coding regions, WES provides a more cost-effective approach than whole genome sequencing.

GENEWIZ provides comprehensive solutions for exome sequencing at the research and clinical level.



Exome Sequencing Service Options

Exome Sequencing for Research Use Only

Our research-grade service provides customizable solutions for human and mouse exome sequencing. Flexible service packages are available to meet your budget and deadline requirements.

Clinical Exome Sequencing

Our clinical workflows are performed in a CLIA-certified lab by CLIA-trained personnel on CLIA-qualified equipment. Receive the highest level of regulatory compliance with our CLIA-validated clinical exome sequencing assay.

Verify your final targets of interest using GENEWIZ’s confirmatory sequencing service.


Exome Sequencing Coverage For Any Application

  • 50x coverage
    (~5 Gb output)

    Germline variant discovery
    Uncovering disease-associated genotypes

  • 100x coverage
    (~10 Gb output)

    Somatic mutation discovery
    Tumor/normal sequencing

  • ≥200x coverage
    (20+ Gb output)

     Low frequency mutation detection
    Measuring tumor mutational burden (TMB)

Features & Benefits

  • Superior Data Quality

    Superior Data Quality

    Exceeding manufacturer's benchmarks

  • Fast Turnaround

    Starting at 1 week for sequencing

  • European Provider

    Sequencing available at our lab in Leipzig, Germany

Dedicated Ph.D. -level support at every step with real-time project updates through our online system

Flexible data amounts starting at 10M read pairs

In-house pipeline for optional Sanger-based confirmatory sequencing of final targets utilizing your NGS samples

Latest platforms - Illumina NovaSeq delivers the highest throughput on the market

Highly scalable - Submit one sample or as many as hundreds

More reasons to choose GENEWIZ

Exome Sequencing Workflow

1. Hybridization Capture

Fragment gDNA, bind probes to exons, and pull down

2. Library Preparation

Add adapters to exon-enriched DNA

3. Sequencing

Sequence 2x150 bp on Illumina® platform

4. Data Analysis

Identify SNVs, INDELs, gene fusions, and CNVs

Webinar| Non-Classical Sources of Tumour-Specific Antigen in Checkpoint Inhibitor Response

Developing immunotherapies for cancer can be difficult due to the variation of immune response from patient to patient. In this webinar, Dr. Litchfield from UCL Cancer Institute presents his team’s exploratory research using a multiomics approach to better understand the diversity of immune response to cancer and highlights their findings of an alternative source of a tumour-specific antigen in checkpoint inhibitor (CPI) response.

How To Order

Email | Phone +49 (0)341 520 122-41